Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis

This article was originally published here

The approval is said to confirm the Cosentyx efficacy in the treatment of axial spondyloarthritis (axSpA) disease spectrus. Cosentyx is claimed to be the first and only fully-human

The post Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply